medigraphic.com
ISSN 0028-3851 (Impreso)

2005, Número 3

<< Anterior Siguiente >>

Rev Neurol Neurocir Psiquiat 2005; 38 (3)


Plasmaféresis en pacientes con enfermedad neuroinmunológica: revisión retrospectiva de 36 casos

García PJA, Salazar-Zúñiga A

Idioma: Español
Referencias bibliográficas: 77
Paginas: 93-106
Archivo PDF: 106.94 Kb.


RESUMEN

Introducción. Las enfermedades neuroinmunológicas constituyen una causa de morbimortalidad e incapacidad importante. Las opciones terapéuticas incluyen esteroides, inmunosupresores, el uso de inmunoglobulina IV, así como plasmaféresis (PF).
Método. Estudio retrospectivo mediante revisión expedientes clínicos de pacientes encamados en el HCM de enero de 1992 a abril del 2000, con miastenia gravis (MG) y síndrome de Guillain-Barré (SGB), que recibieron tratamiento a base de PF. Se revisaron las complicaciones que se presentaron durante o después del procedimiento, y se compararon con las descritas en la literatura mundial.
Resultados. Se revisaron 184 expedientes de pacientes con las enfermedades neuroinmunológicas mencionadas anteriormente, y se observó que sólo 53 pacientes recibieron tratamiento a base de PF, excluyéndose a dos pacientes por abandono del mismo. En los restantes 51 (27.7%) se encontraban 21 (41.1%) con MG tratados con PF, siendo efectiva en 20 de ellos,mostrando en general resultados positivos en 95.2%. En el SGB, 18 (35.2%) pacientes fueron: tratados con PF, siendo útil en 16 (88.8%). Las complicaciones que se presentaron fueron infección del sitio de punción (1.3%), hipotensión (3.5%). Falla del equipo en tres ocasiones.
Conclusión. La PF es útil en pacientes con enfermedades neuroinmunológicas graves siendo similar a la descrita en la literatura mundial, además de ser un procedimiento seguro siempre que se practique por personal capacitado y con experiencia.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ciavarrella D, Wuest D, Strauss RG, et al. Clinical applications of therapeutic apheresis: management of neurologic disorders. J Clin Apheresis 1993; 8: 242-57.

  2. McLeod B, Ciavarrella D, Owen H, AABB Hemapheresis Committee. Guidelines for therapeutic hemapheresis. Bethesda, MD. American Association of Blood Banks, 1995.

  3. Sanders DB, Scoppetta C. The treatment of patients with myasthenia gravis. Neurol Clin 1994; 12: 343-68.

  4. Masselli RA. Pathophysiology of myasthenia gravis and Lambert-Eaton’s syndrome. Neurol Clin 1994; 12: 285-303.

  5. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Neurology 1976; 26: 1054-9.

  6. Richman DP, Wollman RL, Maselli RA, et al. Effector mechanisms of yasthenic antibodies. Ann N Y Scad Sci 1993; 681: 264-73.

  7. Richman DP, Agius MA. Acquired myasthenia gravis. Neurol Clin 1994; 12: 273-84.

  8. Genkins G, Sivak M, Tartter PI. Treatment strategies in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 594-602.

  9. Cornelio F, Antozzi C, Mantegazza R, et al. Immunosuppresive treatments. Their efficacy on myasthenia gravis’ outcome and on the natural course of the disease. Ann N Y Acad Sci 1993; 681: 594-602.

  10. Seybold ME. Plasmapheresis in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 584-7.

  11. D’Empire G, Hoaglin DC, Perlo VP, Pontopidan H. Effect of pre-thymectomy plasma exchange on postoperative respiratory function in myasthenia gravis. J Thorac Cardiovasc Surg 1985; 89: 592-6.

  12. Ichikawa M, Koh CS, Hata Y, et al. Immunoadsorption plasmapheresis for severe generalized myasthenia gravis. Arch Dis Child 1993; 69: 236-8.

  13. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol 1994; 97 (Suppl. 1): 49-51.

  14. Ropper AH. The Guillain-Barré’s syndrome. N Engl J Med 1992; 326: 1130-6.

  15. Hughes RA, Rees JH. Guillain Barré’s syndrome. Curr Opin Neurol 1994; 7: 386-92.

  16. Salazar Zúñiga A, Alegría Loyola MA, Del Ángel Guevara O. Síndrome de Miller Fisher: reporte de dos casos manejados con plasmaféresis. Rev Sanid Milit Mex 2000; 54(2): 100-1.

  17. Van der Meché FGA. The Guillain-Barré’s syndrome. Vaillieres Clin Neurol 1994; 3: 73-94.

  18. Vriesendorp FJ, Mishu B, Blaser MJ, Koski CL. Serum antibodies to GM1, GD16, peripheral nerve mielin, and Campylobacter jejuni in patients with Guillain-Barré’s syndrome and controls. Ann Neurol 1993; 34: 130-5.

  19. McFarlin DE. Immunological parameters in Guillain-Barré. Ann Neurol 1990; 27 (Suppl.): 525-9.

  20. Vriesendorp FJ, Mayer RF, Koski CL. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré’s syndrome treated and not treated with plasmapheresis. Arch Neurol 1991; 48: 858-61.

  21. Koski CL, Gratz E, Sutherland J, et al. Clinical correlation with antiperipheral myelin antibodies in Guillain-Barré’s syndrome. Ann Neurol 1986; 19: 573-7.

  22. Yuki N, Sato S, Tsuji S, et al. Frequent presence of anti-GQ1B antibody in Fisher’s syndrome. Neurology 1993; 43: 414-7.

  23. Ropper AH. The Guillain-Barré’s syndrome. N Engl J Med 1992; 236: 1130-6.

  24. Rees JH, Gregson NA, Hughes RA. Antiganglioside GM1 antibodies in Guillain-Barré’s syndrome and their relationship to campylobacter jejunii infection. Ann Neurol 1995; 38: 809-16.

  25. Rees JH, Soudain SE, Gregson NA, Hughes RAC. Campylobacter jejunii infection and Guillain-Barré’s syndrome. N Engl J Med 1995; 333: 1374-9.

  26. McKhann GM, Cornblath DR, Griffen JW, et al. Acute motor axonal neuropathy: A frequent cause of flaccid paralysis in China. Ann Neurol 1993; 33: 333-42.

  27. Guillain-Barré’s syndrome steroid trial group. Double-blind trial of intravenous methylprednisone in Guillain-Barré’s syndrome. Lancet 1993; 341: 586-90.

  28. Guillain-Barré’s syndrome study group. Plasmapheresis and acute Guillain-Barré’s syndrome. Neurology 1985; 35: 1096-104.

  29. French Cooperative Group on Plasma Exchange in Guillain-Barré. Efficiency of plasma exchange in Guillain-Barré’s syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.

  30. French Cooperative Group on Plasma Exchange in Guillain-Barré. Plasma exchange in Guillain-Barré’s syndrome: one-year follow-up. Ann Neurol 1992; 32: 94-7.

  31. Rudnicki S, Vriesendorp F, Koski CL, Mayer RF. Electrophysiologic studies in the Guillain-Barré’s syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve 1992; 15: 57-62.

  32. Bouget J. Chevret S, Chastang C, et al. Plasma exchange in Guillain-Barré’s syndrome: results from the prospective, double-blind, randomized, multicenter study. Crit Care Med 1993; 21: 651-8.

  33. Grishaber JE, Cunningham MC, Rohret PA, Strauss RG. Analysis of venous access for therapeutic plasma exchange in patients with neurological disease. J Clin Apheresis 1992; 7: 119-23.

  34. Van der Meché FGA, Schmitz PIM, and the dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326: 1123-9.

  35. Irani DN, Cornblath DR, Chaudrhry V, et al. Relapse in Guillain-Barré’s syndrome after treatment with human immune globulin. Neurology 1993; 43: 872-5.

  36. Bleck TP, IVIG for GBS: Potential problems in the alphabet soup. Neurology 1993; 43: 857-8.

  37. Osterman PO, Lundemo G, Pirskanen R, Fagius J, Pihlstedt P, Siden A. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1984; 2: 1296-8.

  38. Guillain-Barré Study Group. Plasmapheresis and acute Guillain-Barré’s syndrome. Neurology 1985; 35: 1096-104.

  39. Dyck PJ, Daube J, O’Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314: 461-5.

  40. McEvoy KM. Treatment of Lambert-Eaton’s myasthenic syndrome. In: Lisak RP (ed.). Handbook of myasthenia gravis and myasthenic syndromes. New York: Dekker; 1994, p. 409-15.

  41. Khatri BO, McQuillen MP, Harrington GJ, Schmoll D, Hoffmann RG. Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 1985; 35: 312-9.

  42. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6.

  43. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993; 43: 1100-4.

  44. Dyck PJ, O’Brien PC, Oviatt KF, et al. Pednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11: 136-41.

  45. Hahn AF, Bolton CF, Vandervoort P, Feasby TE, Zochodne D. Intravenous immunoglobulin treatment (IVIG) in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind placebo-controlled crossover study [abstract]. Neurology 1995; 45 (Suppl. 4): A416.

  46. Pinching AJ, Peters DK, Newsom-Davis JN. Remission of myasthenia gravis following plasma exchange. Lancet 1976; 2: 1373-6.

  47. Mendell JR. Chronic inflammatory demyelinating polyradiculopathy. Annu Rev Med 1993; 44: 211-9.

  48. MacLeod BC. The technique of therapeutic apheresis. J Crit Illness 1991; 6: 487-95.

  49. Farkkila M, Penttila P. Plasma exchange therapy reduces the nursing care needed in Guillain-Barré’s syndrome. J Adv Nurse 1992; 17: 672-5.

  50. Van Doorn PA, Vermeulen M, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic demielinating polyneuropathy. Arch Neurol 1991; 48: 217-20.

  51. Jablecki C. Lambert-Eaton myasthenic syndrome. Muscle nerve 1984; 7: 250-7.

  52. Dau PC, Denys EH. Plasmapheresis and immunosupressive drug theraphy in the Eaton-Lambert’s syndrome. Ann Neurol 1982; 11: 570-5.

  53. Hewett SJ, Atchinson WD. Specificity of Eaton-Lambert’s myasthenic syndrome immunoglobulin for nerve terminal calcium channels. Brain Res 1992; 599: 324-32.

  54. Rosenfield MR, Wong E, Dalmace J, et al. Cloning and characterization of an Eaton-Lambert’s myasthenic syndrome antigen. Ann Neurol 1993; 33: 113-20.

  55. Lisak RP. Plasma exchange in neurology disease. Arch Neurol 1984; 41: 654-7.

  56. Weinshenker BG, Sibley WA. Natural history and treatment of multiple sclerosis. Curr Opin Neurol Neurosurg 1992; 5: 203-11.

  57. Goodkin DE, Ransohoff RM, Rudick RA. Experimental theraphies for multiple sclerosis. Current Status Cleve Clin J Med 1992; 59: 63-4.

  58. Goodin DS. The use of immunosupressive agents in the treatment of multiple sclerosis: a critical review. Neurology 1991; 41: 980-5.

  59. Jacobs L, Goodkin DE, Rudick LA, Herndon R. Advances in specific therapy for multiple sclerosis. Curr Opin Neurol 1994; 7: 250-4.

  60. Van Oosten BW, Truyen L, Barkhof F, Polman CH. Multiple sclerosis therapy. A practical guide. Drugs 1995; 49: 200-12.

  61. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268-76.

  62. Dau PC, Pentajan JM, Johnson KP, et al. Plasmapheresis and immunosuppresive drug therapy in multiple sclerosis. Neurology 1980; 30: 1023-8.

  63. Khatri BO, McQuillen MP, Hoffman RG, et al. Plasma exchange in chronic progressive multiple sclerosis: Along term study. Neurology 1991; 41: 409-14.

  64. Consensus Conference. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986; 256: 1333-7.

  65. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 1977; 297: 1134-40.

  66. Newsom-Davis J, Pinching AJ, Wilson SG. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 1978; 28: 266.

  67. Rodnitzky RL, Goeken JA. Complications of plasma exchange in neurological patients. Arch Neurol 1982; 39: 350-3.

  68. French Cooperative Group on Plasma Exchange in Guillain-Barré’s Syndrome. Efficacy of plasma exchange in Guillain-Barré’s syndrome: role of replacement fluids. Ann Neurol 1987; 22: 753-61.

  69. Lisak RP, Abramsky O, Schotland DL. Plasmapheresis in the treatment of myasthenia gravis: preliminary study in 21 patients. In: Dau PC (ed.). Plasmapheresis and the immunobiology of myasthenia gravis. Boston: Houghton Mifflin; 1979, p. 209-15.

  70. Newsom-Davis J, Vincent A, Wilson SG, Ward CD. Long-term effects of repeated plasma exchange in myasthenia gravis. Lancet 1979; 1: 464-8.

  71. Chaudhry V, Cornblath DR. Immunosuppressive therapy for myasthenia gravis. In: Lisak RP (ed.). Handbook of myasthenia gravis. New York: Marcel Dekker; 1994, p. 341-74.

  72. Newsom-Davis J. Murray NMF. Plasma exchange and immunosuppressive drug treatment in the Eaton-Lambert’s myasthenic syndrome. Neurology 1984; 34: 480-5.

  73. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune etiology for acquired neuromyotonia (Isaacs’ syndrome). Lancet 1991; 338: 75-7.

  74. Agnello-Dimitrijevic W, Moore PM. Plasmapheresis in CNS-SLE (abstract). Neurology 1994; 44 (Suppl. 2): A276-A277.

  75. Berkman EM, Orlin JB. Use of plasmapheresis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 1980; 20: 171-8.

  76. Chad D, Pariser K, Bradley WG, Adelman LS, Pinn VW. The pathogenesis of cryoglobulinemic neuropathy. Neurology 1982; 32: 725-9.

  77. Graus F, Vega F, Delattre JY, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology 1992; 42: 536-40.




2020     |     www.medigraphic.com